Ann Beliën contributes to development of the Janssen Prevention Center’s discovery portfolio in two main ways. In her Management Team role as Head of Strategy, she is responsible for providing the Global Head of the Janssen Prevention Center with a clear and precise strategy overview, based on the synthesis of diverse information needed for strategic decision-making. As Head of External Innovation, she supports Johnson & Johnson’s global search for the best science and technologies to advance healthcare, focusing on opportunities that fit the Janssen Prevention Center’s mandate to drive innovation in the field of prevention.
Ann joined Johnson & Johnson in 2000 and has worked in a wide range of roles in different parts of Janssen, gaining experience in drug discovery and development through to launch, R&D due diligence, external collaboration, cross-functional project management and company integration. Ann’s pharmaceutical research has embraced small and large molecules for therapeutic or preventive use, in the areas of oncology, neuroscience and virology. She has a Ph.D. in Neuro-oncology and is a certified Project Management Professional.
Ann was a strong advocate for Johnson & Johnson entering the area of disease prevention and took part in assessments leading to the acquisition of vaccine company Crucell in 2011. After helping to facilitate the integration of Crucell into the Janssen organization, Ann joined the Crucell Vaccine Institute in 2012 as Senior Director R&D Strategy Development. In this role she made an important contribution to proactive portfolio management.
View Ann’s LinkedIn Profile here.